A series of programmed death protein 1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors (avelumab, atezolizumab, durvalumab, nivolumab, and pembrolizumab) have been approved for use in patients with locally advanced or metastatic urothelial carcinoma by the Food and Drug Administration.[34] When PD-1 and PD-L1 block the PD-1/PD-L1/2 signaling pathway, T lymphocytes are activated to kill tumor cells.[35] Up to date, there have been no reports on the therapeutic effects of immunotherapy in BC. The gene discussed is CD274; the disease is breast cancer.